This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. The FDA cleared BrainsWay D treatment of Major Depression in patients who failed to respond to one or more anti-depressants in the current episode.
Treatment-resistant depression (TRD) poses a significant challenge for psychiatrists. The challenge of treating patients with TRD is compounded by the lack of a consensus definition and a paucity of evidence-based medicine to provide guidance.
As a caring physician, you are dedicated to delivering exceptional patient care, yet recognize that the growth of your practice is mainly dependent on time. Psychiatrists now have a device to comprehensively treat TRD after the failure of medications and not refer to larger centers. Currently, Brainsway Deep TMS systems are treating patients in leading institutions and private mental health clinics all over the world.
During the webinar Dr. Aron Tendler will discuss the Clinical, Technical and financial aspect of adding Deep TMS to your depression treatment tool box. Among the topics, Dr. Tendler will focus on:
When? Thursday, April 14th, at 8pm EST